Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 9/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4357136 | 0.98 | PDE4B (0.41) | PDE4BCHRM3ENPP2TLR8TLR7 | |
| SCHEMBL4356983 | 0.98 | PDE4B (0.43) | PDE4BCHRM3ENPP2TLR8TLR7 | |
| SCHEMBL4349680 | 0.96 | PDE4B (0.44) | PDE4BCHRM3ENPP2ADORA2APDE5A | |
| SCHEMBL4347458 | 0.95 | PDE4B (0.41) | PDE4BCHRM3ENPP2TLR8TLR7 | |
| SCHEMBL4353743 | 0.95 | PDE4B (0.43) | PDE4BCHRM3ENPP2ADORA2APDE5A | |
| SCHEMBL4348648 | 0.94 | PDE4B (0.44) | PDE4BCHRM3ENPP2ADORA2APDE5A | |
| SCHEMBL1363837 | 0.94 | PDE4B (0.45) | PDE4BCHRM3ENPP2PIK3CAMTOR | |
| SCHEMBL4098917 | 0.94 | PDE4B (0.45) | PDE4BCHRM3ENPP2TLR8TLR7 | |
| SCHEMBL4349693 | 0.94 | CHRM3 (0.47) | PDE4BCHRM3ENPP2 | |
| SCHEMBL4364432 | 0.93 | PDE4B (0.43) | PDE4BCHRM3ENPP2ADORA2APDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071588-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | claimed |
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | claimed |
| US-8071588-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4A, PDE4B, PDE1A | PDE4B 2/4885CHRM3 20/4885ENPP2 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.